CME CirclePrint this Activity for Offline ReferenceInstructions on Taking Medscape CME

New Insights Into COX-2 Specific Inhibition for Pain and Arthritis Therapy CME
Faculty: Chairperson: Kim Fagan, MD, LLC; Faculty: Jeffrey A. Katz, MD; Roland W. Moskowitz, MD; Jay L. Goldstein, MD; William B. White, MD, FACP
Disclosures

Release Date: October 14, 2002; Valid for credit through October 14, 2003

This activity has expired.
CME in this activity indicates that it was developed according to ACCME guidelines and was certified for credit by one or more accredited CME or CE providers. Medscape cannot attest to the timeliness of expired CME activities.


This CME activity, "New Insights Into COX-2 Specific Inhibition for Pain and Arthritis Therapy", was originally offered as a CD-ROM certified for CME.

Contents of This CME Activity

Medscape Editorial Note, February 9, 2005

Since the writing of this content, certain published data analyses and public announcements have called into question the cardiovascular safety of some of the COX-2 inhibitors and standard NSAIDs. Results of such publications may have affected certain information contained in this article, causing it to be outdated or possibly inaccurate. In order to keep our members current on this important therapeutic area, Medscape is providing regularly updated information related to NSAIDs in the Medscape NSAID Alert Center. This center includes commentary, abstracts, and statements from the US Food and Drug Administration, National Institutes of Health, and other policy makers, as well as other articles that are intended to provide supplementary information for assessing the accuracy of this content.

This program is offered in two formats. Please choose one of the versions:

    Flash Version
    (A multimedia presentation with synchronized audio, slides and transcript.)
    Note: Macromedia's Flash Player 5 plug-in is required to view the Flash version.
    Download the Macromedia Flash Player 5 plug-In:

    Get Flash 5

    --OR--

    Slides with transcript and RealAudio:

  1. Welcome and Introduction
    Pain Conditions
    About Pain
    Arthritis: Morbidity and Mortality From the Disease Process and Its Treatment
    Pain Management

  2. Redefining the Management of Pain
    Why We Need to Redefine Pain
    Pain Mechanisms and COX-2 Neurophysiology
    Using COX-2 Inhibition for Pain Management
    Valdecoxib and Rofecoxib
    Implications and Conclusions

  3. COX-2 Specific Inhibitors: New Clinical Findings
    Nonsteroidal Anti-inflammatory Drugs: Not Without Their Problems
    The COX-2 Specific Inhibitors
    Safety of COX-2 Specific Inhibitors in Effects on Platelets
    The Ankle Sprain Study
    The Shoulder Pain Study
    Don't Wait for Pain: Preoperative Treatment
    Postoperative Pain
    A Gain in Safety With COX-2 Specific Inhibitors
    Peripheral Edema
    Findings From Comparator Trials
    A Look at Other Adverse Events

  4. Enhancing the Gastrointestinal Safety and Tolerability Profile of Pain and Arthritis Therapy
    The Problem With Nonsteroidal Anti-inflammatory Drugs
    COX-2 Inhibitors: Effect on Platelets
    COX-2 Inhibitors and the Gastrointestinal Mucosa
    Outcomes Trials With COX-2 Specific Inhibitors
    The CLASS Trial
    The VIGOR Trial
    SUCCESS I
    Conclusions on COX-2 Specific Inhibitors
    Adverse Events From Outcomes Trials

  5. A Cardiovascular and Renal Assessment of Pharmacological Agents Used in Pain and Arthritis Therapy
    Examining Cardiorenal Physiology, Syndromes and Influences
    Effects of Various COX-2 Inhibitors: Study Findings
    A Study of Celecoxib vs Rofecoxib in Osteoarthritis Patients With Hypertension
    The Cardiovascular Aspect of COX-2 Inhibitors
    A Look at Cardiovascular Thrombolic Events in Outcomes Trials
    Valdecoxib, Naproxen, and Aspirin and Cardiovascular Events

These educational activities, certified by accredited providers, were not prepared by Medscape's editors, but are made available on our site as a service to our audience. Authors are routinely instructed by the provider to disclose significant financial relationships and mention of investigational drugs and unapproved indications. Medscape has received a fee for posting these activities. Direct questions or comments to: CME@webmd.net.

 
Legal Disclaimer
The material presented here does not necessarily reflect the views of Medscape, the CME provider, the companies providing educational grants or the authors and writers. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers and continuing education participants should verify all information and consult a qualified healthcare professional before treating patients or utilizing any therapeutic product discussed in this educational activity.

 
Copyright © 2002 M2 Communications. Postgraduate Institute for Medicine is pleased to acknowledge the developmental support of this activity by M2 Communications.
Pfizer
  • This activity has expired.

    The accredited provider can no longer issue certificates for this activity. Medscape cannot attest to the timeliness of expired CME activities.

  • CME Information
All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.